Cytokinetics (CYTK) Announces Proposed $150M Share Common Offering

Cytokinetics, Incorporated (NASDAQ: CYTK) today announced plans to offer, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock in the offering will be sold by Cytokinetics.

Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering. Barclays Capital Inc. is acting as an additional book-running manager for the offering.

The securities described above are being offered by Cytokinetics pursuant to a shelf registration statement (including a prospectus) filed on November 6, 2019 with the Securities and Exchange Commission (SEC), which has become automatically effective.

You May Also Be Interested In

• Osprey Acquisition Corp. III prices $261M IPO on Nasdaq
• Owlet secures $25M Wells Fargo credit facility, cutting borrowing costs
• ITG prices IPO at $16 per share on Nasdaq